title: A report from the European Society of Cardiology Congress 2013 (August 31-September 4, 2013 - Amsterdam, the Netherlands).
abstract: Many are the diseases that can affect the heart and the vessels, most of which were discussed during the European Society of Cardiology Congress 2013 in Amsterdam. With an attendance of almost 30,000 delegates buzzing the halls of the RAI convention center, Amsterdam was the capital of cardiologic science this summer, and a big challenge for any attendee trying to get the most out of all the oral and poster sessions missing the minimum of new science being presented. Thomson Reuters Cortellis™ supplements the information for any scientist who missed an important session, with a particular focus on new investigational drugs, many of them still in preclinical research, which will certainly impact how cardiovascular disorders are treated in a foreseeable future. Clinical and preclinical research advance to bring novel therapeutic targets, new drugs and new insight into patient characteristics requiring particular treatment approaches. This report is a sample of the new science discussed during the 5 days of meetings.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D002317:Cardiovascular Agents
keywords: Atrial fibrillation; Cardiovascular diseases; Coronary artery disease; Heart failure; Hypertension